Cardiac Function and Serum Biomarkers throughout Staged Fontan Palliation: A Prospective Observational Study

• Published in: Journal of cardiovascular development and disease Vol. 10; no. 7; p. 289
• Main Authors: van der Ven, J P G, Kamphuis, V P, van den Bosch, E, Gnanam, D, Terol, C, Bogers, A J J C, Breur, J M P J, Berger, R M F, Blom, N A, Ten Harkel, A D J, Koopman, L, Helbing, W A
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.07.2023; MDPI
• Subjects: Analysis; Biological markers; Biomarkers; Blood; Cardiomyocytes; Cardiovascular disease; Congenital diseases; congenital heart disease; Coronary artery bypass; Datasets; Ethylenediaminetetraacetic acid; Fontan palliation; Heart; Heart surgery; Hospitals; Medical examination; Medical research; Medicine, Experimental; Observational studies; Patients; Proteins; single ventricle; Surgical outcomes; Ultrasonic imaging; Netherlands; Norway; congenital heart disease; Fontan palliation; single ventricle; biomarkers
• ISSN: 2308-3425; 2308-3425
• DOI: 10.3390/jcdd10070289

Fontan patients undergo multiple cardiothoracic surgeries in childhood. Following these procedures, ventricular function is temporarily decreased, and recovers over months. This is presumably related to cardiopulmonary bypass, but this is incompletely understood. Throughout the Fontan palliation, cardiac function is also affected by volume unloading. We aimed to gain insight into the biological processes related to impaired ventricular function and recovery following Fontan palliations using a panel of biomarkers. Furthermore, we described changes in ventricular function across the Fontan palliation due to volume unloading. We performed a prospective multicenter observational study in patients undergoing partial (PCPC) or total cavo-pulmonary connection (TCPC). Patients underwent assessment-including echocardiography and blood sampling-before surgery (T1), at first follow-up (T2), and 1 year after their procedures (T3). Blood samples were analyzed using a biomarker panel (OLINK CVD-III). Ninety-two biomarkers were expressed as principal components (PC) to limit multiple statistical testing. We included 32 PCPC patients aged 7.2 [5.3-10.3] months, and 28 TCPC patients aged 2.7 [2.2-3.8] years. The single ventricular longitudinal strain (SV GLS) temporarily decreased for PCPC patients at T2 (-15.1 ± 5.6 (T1) to -13.5 ± 5.2 (T2) to -17.3 ± 4.5 (T3), < 0.047 for all differences), but not following TCPC. The serum biomarkers were expressed as 4 PCs. PC1, including biomarkers of cell-cell adhesion, was not related to any patient characteristic. PC2, including biomarkers of superoxide anion regulation, increased at T2. PC3, including biomarkers of cardiovascular development, related to the stage of Fontan palliation. PC4 was of uncertain biological or clinical significance. No PC was found that related to ventricular performance. The SV GLS was temporarily diminished following PCPC, but not following TCPC. Several biomarkers were related to post-operative stress and adaptation to the PCPC or TCPC circulation, but none were related to the outcome.